No Data
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis Gets FDA Clearance for First Approved Treatment For Rare Kidney Disease
Reported Earlier, Novartis Secures Third FDA Approval For Oral Fabhalta In Rare Kidney Disease C3G
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Monte Rosa to Focus on Prostate Cancer Only for Oncology Asset MRT-2359
Novartis Reports Updated Positive Data From Phase III SMA Program
